Wet Lab Services
Your Drug Discovery & Development Partners
Discovery to CMC
Pharmaceutics. Development of analytical methods & prototype formulations & testing efficacy of formulations. Impurity identification. Solubility assessment. Stability testing. Permeability into cells. Off target screening using ‘omics. Cytotoxicity. Chemistry, Manufacture and Control (CMC). ADME.
Hollow Fiber Model
Client customized hollow fiber system models with and without 3D human organotypic models, PBMCs, and next generation post-hollow fiber system preclinical model studies. Design of combination regimens to find best drugs and best doses to combine, using factorial design and human-based pharmacokinetics.
Predicting Clinical Toxicity & Further Mechanisms of Effect
Dose-effect testing using human 3D organotypic organoids & predicted human PKs. Readouts: next generation sequencing and multiple ‘omics. Comparison of signatures with Praedicare’s proprietary database of signatures of known drugs using AI.
Discovery to CMC
Pharmaceutics. Development of analytical methods & prototype formulations & testing efficacy of formulations. Impurity identification. Solubility assessment. Stability testing. Permeability into cells. Off target screening using ‘omics. Cytotoxicity. Chemistry, Manufacture and Control (CMC). ADME.
Hollow Fiber Model
Client customized hollow fiber system models with and without 3D human organotypic models, PBMCs, and next generation post-hollow fiber system preclinical model studies. Design of combination regimens to find best drugs and best doses to combine, using factorial design and human-based pharmacokinetics.
Predicting Clinical Toxicity & Further Mechanisms of Effect
Dose-effect testing using human 3D organotypic organoids & predicted human PKs. Readouts: next generation sequencing and multiple ‘omics. Comparison of signatures with Praedicare’s proprietary database of signatures of known drugs using AI.
Case Studies
View Praedicare’s case studies on cancer, human immune system based responses, toxicology with 3D human organotypic models, viruses, fungal infection, protozoa, rapidly growing and slow growing mycobacteria, Gram-positive and Gram-negative bacteria.
VIEW OUR CASE STUDIES
Viruses, candida and other yeasts, malaria [Plasmodium species], leishmania and most bacterial pathogens including mycobacteria
TB Combination Regimens
Pre-clinical HFS models, combination regimens and clinical translation
Non-Tuberculosis Mycobacterium Combination Regimens
Pre-clinical HFS models, combination regimens and clinical translation
Solid cancers and hematological malignancies
Pre-clinical HFS models, including with a bone marrow, advanced DNA-seq, methylation, and RNA-seq, combination regimens and clinical translation
Safety Pharmacology and Toxicology
Pre-clinical HFS models, 3D human organotypic models, advanced multi-omics, database of known clinical toxins and machine learning
Pharmacokinetics / Tissue Distribution
Pre-clinical HFS models, 3D human organotypic models, LC/MS/MS quantitation Nonlinear dynamical sink models to map physiological and pathological pathways to organ anatomy and drug concentrations based on 3D human organoids, human pathology samples and biopsies
INTERESTED IN LEARNING MORE?
Contact Us Today
19
Number of Biopharma
Companies Worked With
51
Number of Projects
Worked On
INTERESTED IN LEARNING MORE?
Contact Us Today
21
56
Number of Biopharma
Companies Worked With
Number of Projects
Worked On